Literature DB >> 25996614

Mild clinical behaviour of Crohn disease in elderly patients in a Latin American country: A case-control study.

Jesús K Yamamoto-Furusho, Andrea Sarmiento-Aguilar.   

Abstract

BACKGROUND: Crohn disease is characterized by fluctuating clinical behaviour, which is influenced by various factors. There are no data from Latin America that evaluate the clinical behaviour of Crohn disease in elderly patients.
OBJECTIVE: To evaluate the clinical course of elderly onset Crohn disease compared with younger onset in the Mexican population.
METHODS: The present analysis was a case-control study that included 132 patients with a histopathological diagnosis of Crohn disease between 1983 and 2013 in an inflammatory bowel disease clinic of a tertiary care centre. Statistical analysis was performed using SPSS version 17 (IBM Corporation, USA) and descriptive statistics, χ2 and Fisher's exact test for categorical variables and Student's t test for numerical variables. Univariate and multivariate analysis were performed to identify associated risk factors and OR was calculated.
RESULTS: A total of 132 patients (73 men and 59 women) were divided into two groups according to age at diagnosis: 27 cases (>60 years of age) and 105 controls (≤60 years of age). Factors influencing the clinical course of Crohn disease in the elderly were: female sex (OR 2.55 [95% CI 1.06 to 6.10]; P=0.02); colonic location (OR 0.22 [95% CI 0.03 to 0.89]; P=0.02); mild clinical behaviour of disease (OR 10.08 [95% CI 3.74 to 27.17]; P=0.0001); response to medical treatment (OR 2.85 [95% CI 1.08 to 7.48]; P=0.02); frequent use of sulfasalazine (OR 4.46 [95% CI 1.22 to 16.28]; P=0.03); less use of azathioprine (OR 0.38 [95% CI 0.13 to 1.03]; P=0.04); and long-term remission (OR 4.96 [95% CI 1.70 to 14.48]; P=0.002). CONLCUSION: Elderly patients with Crohn disease had a mild clinical course characterized by the lack of escalation to immunosuppressive and anti-tumour necrosis factor therapy, as well as long-term remission.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25996614      PMCID: PMC4699598          DOI: 10.1155/2015/473726

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  45 in total

1.  The epidemiology of inflammatory bowel disease in Canada: a population-based study.

Authors:  Charles N Bernstein; Andre Wajda; Lawrence W Svenson; Adrian MacKenzie; Mieke Koehoorn; Maureen Jackson; Richard Fedorak; David Israel; James F Blanchard
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

Review 2.  Ageing and the gut.

Authors:  Edward Britton; John T McLaughlin
Journal:  Proc Nutr Soc       Date:  2012-11-12       Impact factor: 6.297

3.  Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival.

Authors:  E V Loftus; M D Silverstein; W J Sandborn; W J Tremaine; W S Harmsen; A R Zinsmeister
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

4.  Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry.

Authors:  Melvin B Heyman; Barbara S Kirschner; Benjamin D Gold; George Ferry; Robert Baldassano; Stanley A Cohen; Harland S Winter; Patricia Fain; Chris King; Terry Smith; Hashem B El-Serag
Journal:  J Pediatr       Date:  2005-01       Impact factor: 4.406

5.  Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD.

Authors:  Cary G Sauer; Subra Kugathasan
Journal:  Med Clin North Am       Date:  2010-01       Impact factor: 5.456

6.  Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study.

Authors:  Subra Kugathasan; Robert H Judd; Raymond G Hoffmann; Janice Heikenen; Gregorz Telega; Farhat Khan; Sally Weisdorf-Schindele; William San Pablo; Jean Perrault; Roger Park; Michael Yaffe; Christopher Brown; Maria T Rivera-Bennett; Issam Halabi; Alfonso Martinez; Ellen Blank; Steven L Werlin; Colin D Rudolph; David G Binion
Journal:  J Pediatr       Date:  2003-10       Impact factor: 4.406

7.  Comparative outcomes of younger and older hospitalized patients with inflammatory bowel disease treated with corticosteroids.

Authors:  Nicholas K Weber; David H Bruining; Edward V Loftus; William J Tremaine; Jessica J Augustin; Brenda D Becker; Patricia P Kammer; William Scott Harmsen; Alan R Zinsmeister; Darrell S Pardi
Journal:  Inflamm Bowel Dis       Date:  2013-11       Impact factor: 5.325

8.  Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?

Authors:  W Miehsler; W Reinisch; E Valic; W Osterode; W Tillinger; T Feichtenschlager; J Grisar; K Machold; S Scholz; H Vogelsang; G Novacek
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

9.  Inflammatory bowel disease in children 5 years of age and younger.

Authors:  Petar Mamula; Grzegorz W Telega; Jonathan E Markowitz; Kurt A Brown; Pierre A Russo; David A Piccoli; Robert N Baldassano
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

Review 10.  Aging of the human metaorganism: the microbial counterpart.

Authors:  Elena Biagi; Marco Candela; Susan Fairweather-Tait; Claudio Franceschi; Patrizia Brigidi
Journal:  Age (Dordr)       Date:  2011-02-24
View more
  2 in total

1.  Epidemiology of inflammatory bowel disease in Mexico and Colombia: Analysis of health databases, mathematical modelling and a case-series study.

Authors:  Agustín Ciapponi; Sacha Alexis Virgilio; Mabel Berrueta; Natalie Claire Soto; Álvaro Ciganda; Moisés Freddy Rojas Illanes; Briseida Rubio Martinez; Johana Gamba; Carlos Arturo González Salazar; José Nicolás Rocha Rodríguez; Bruno Scarpellini; Ana María Bravo Perdomo; Gerardo Machnicki; Leandro Aldunate; Juan De Paula; Ariel Bardach
Journal:  PLoS One       Date:  2020-01-27       Impact factor: 3.240

Review 2.  Management of inflammatory bowel disease in older persons: evolving paradigms.

Authors:  Saurabh Kedia; Jimmy K Limdi; Vineet Ahuja
Journal:  Intest Res       Date:  2018-04-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.